{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:28:00Z","timestamp":1793284080817,"version":"4.5.0"},"reference-count":42,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the impact of elevated body mass index (BMI) in the achievement of minimal disease activity (MDA) and several definitions of remission in patients with psoriatic arthritis (PsA) in Switzerland. Secondarily, to assess the overlapping across the study outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational cohort study in the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry included patients with PsA starting their first biologic or targeted synthetic disease-modifying antirheumatic drug (b\/tsDMARD) from 1997 to 30 June 2018. Exposure was BMI category at b\/tsDMARD start: overweight, obese, and normal weight (reference). Logistic regression was used to assess the achievement of MDA and remission at \u226412\u2009months, as well as treatment persistence at 1\u2009year, in overweight patients and patients with obesity compared with the normal weight group. Remission was defined by Disease Activity for Psoriatic Arthritis (DAPSA), clinical DAPSA (cDAPSA) and 28-joint Disease Activity Score (DAS28). Additionally, overlapping across study outcomes was investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 306 (39.5%) normal weight patients, 285 (36.8%) overweight patients and 183 (23.6%) patients with obesity. Compared with the normal weight group, patients with obesity had lower odds of achieving MDA at \u226412\u2009months (adjusted OR (ORadj) 0.45, 95% CI 0.24 to 0.82). This was consistent with the observed reduced odds of achieving DAPSA-remission (ORadj 0.42, 95%\u2009CI 0.21 to 0.85), cDAPSA-remission (ORadj 0.51, 95%\u2009CI 0.27 to 0.96) and DAS28-remission (ORadj 0.51, 95%\u2009CI 0.32 to 0.81) in patients with obesity versus normal weight patients. Among the 125 patients achieving MDA, the majority (81.8% normal weight, 80.0% overweight, 78.9% obese) achieved cDAPSA-remission. No differences were observed in the odds to achieving treatment persistence between the BMI strata.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Obesity halved the likelihood of achieving MDA and remission in patients with PsA with b\/tsDMARDs compared with those with normal weight, while it did not impact treatment persistence. High overlapping of patients achieving the outcomes MDA and cDAPSA-remission was observed across every BMI group.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-061474","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T11:25:59Z","timestamp":1663413959000},"page":"e061474","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5911-2037","authenticated-orcid":false,"given":"Enriqueta","family":"Vallejo-Yag\u00fce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1313-4473","authenticated-orcid":false,"given":"Theresa","family":"Burkard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-7304","authenticated-orcid":false,"given":"Raphael","family":"Micheroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-8530","authenticated-orcid":false,"given":"Andrea Michelle","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"2022091704251120000_12.9.e061474.1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2022091704251120000_12.9.e061474.2","first-page":"819","article-title":"MArche pain prevalence, investigation group (MAPPING) study. prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study","volume":"23","author":"Salaffi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2022091704251120000_12.9.e061474.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"2022091704251120000_12.9.e061474.4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2022091704251120000_12.9.e061474.5","article-title":"Adipokines, cardiovascular risk, and therapeutic management in obesity and psoriatic arthritis","volume":"11","author":"Porta","year":"2020","journal-title":"Front Immunol"},{"key":"2022091704251120000_12.9.e061474.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2022091704251120000_12.9.e061474.7","doi-asserted-by":"crossref","first-page":"700.1","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022091704251120000_12.9.e061474.8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"key":"2022091704251120000_12.9.e061474.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker349"},{"key":"2022091704251120000_12.9.e061474.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204448"},{"key":"2022091704251120000_12.9.e061474.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160532"},{"key":"2022091704251120000_12.9.e061474.12","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/jcm10143194","article-title":"Comparison of psoriatic arthritis and rheumatoid arthritis patients across body mass index categories in Switzerland","volume":"10","author":"Vallejo-Yag\u00fce","year":"2021","journal-title":"J Clin Med"},{"key":"2022091704251120000_12.9.e061474.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21711"},{"key":"2022091704251120000_12.9.e061474.14","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1194-8","article-title":"Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis","volume":"18","author":"Lupoli","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2022091704251120000_12.9.e061474.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew326"},{"key":"2022091704251120000_12.9.e061474.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"2022091704251120000_12.9.e061474.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.07.001"},{"key":"2022091704251120000_12.9.e061474.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes242"},{"key":"2022091704251120000_12.9.e061474.19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/cells10020216","article-title":"Adipokines and autoimmunity in inflammatory arthritis","volume":"10","author":"Neumann","year":"2021","journal-title":"Cells"},{"key":"2022091704251120000_12.9.e061474.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202812"},{"key":"2022091704251120000_12.9.e061474.21","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8595-z"},{"key":"2022091704251120000_12.9.e061474.22","unstructured":"Die SCQM Foundation (Swiss clinical quality management in rheumatic diseases). Available: https:\/\/www.scqm.ch\/en\/ueber-uns\/ [Accessed 18 May 2021]."},{"key":"2022091704251120000_12.9.e061474.23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001002"},{"key":"2022091704251120000_12.9.e061474.24","first-page":"1","article-title":"mice: multivariate imputation by Chained equations in R","volume":"45","author":"van","year":"2011","journal-title":"J Stat Software"},{"key":"2022091704251120000_12.9.e061474.25","unstructured":"R Core Team . R: a language and environmental for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2020. https:\/\/www.r-project.org\/"},{"key":"2022091704251120000_12.9.e061474.26","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.715186"},{"key":"2022091704251120000_12.9.e061474.27","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0030-y","article-title":"Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity","volume":"2","author":"Coates","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2022091704251120000_12.9.e061474.28","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/rheumatology\/kez305","article-title":"Assessment of the many faces of PSA: single and composite measures in PSA clinical trials","volume":"59","author":"McGagh","year":"2020","journal-title":"Rheumatology"},{"key":"2022091704251120000_12.9.e061474.29","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.4.972"},{"key":"2022091704251120000_12.9.e061474.30","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.8.1986"},{"key":"2022091704251120000_12.9.e061474.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.22.2131"},{"key":"2022091704251120000_12.9.e061474.32","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000327"},{"key":"2022091704251120000_12.9.e061474.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0718-4"},{"key":"2022091704251120000_12.9.e061474.34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","article-title":"Infliximab pharmacokinetics in inflammatory bowel disease patients","volume":"30","author":"Ternant","year":"2008","journal-title":"Ther Drug Monit"},{"key":"2022091704251120000_12.9.e061474.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.07.001"},{"key":"2022091704251120000_12.9.e061474.36","unstructured":"f\u00fcr SB . \u00dcbergewicht und Adipositas - Schweizerische Gesundheitsbefragung 2017 | Publikation. Bundesamt f\u00fcr Statistik, 2020. Available: https:\/\/www.bfs.admin.ch\/asset\/de\/14147705 [Accessed 5 Jun 2022]."},{"key":"2022091704251120000_12.9.e061474.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.027649"},{"key":"2022091704251120000_12.9.e061474.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2022091704251120000_12.9.e061474.39","unstructured":"Body mass index - BMI. Available: https:\/\/www.euro.who.int\/en\/health-topics\/disease-prevention\/nutrition\/a-healthy-lifestyle\/body-mass-index-bmi [Accessed 23 Jun 2021]."},{"key":"2022091704251120000_12.9.e061474.40","unstructured":"Obesity and overweight. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight [Accessed 8 Jul 2021]."},{"key":"2022091704251120000_12.9.e061474.41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.11622\/smedj.2019057","article-title":"A systematic review of the association of obesity with the outcomes of inflammatory rheumatic diseases","volume":"60","author":"Lee","year":"2019","journal-title":"Singapore Med J"},{"key":"2022091704251120000_12.9.e061474.42","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14712598.2022.1998448","article-title":"Cardiometabolic comorbidity in the selection of treatment in spondyloarthritis: one step closer to truly personalized medicine?","volume":"21","author":"Queiro","year":"2021","journal-title":"Expert Opin Biol Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-061474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T11:26:32Z","timestamp":1663413992000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-061474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,17]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjopen-2022-061474"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-061474","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}